Translating Sleeping Beauty transposition into cellular therapies: Victories and challenges

✍ Scribed by Zsuzsanna Izsvák; Perry B. Hackett; Laurence J.N. Cooper; Zoltán Ivics

• Publisher: John Wiley and Sons
• Year: 2010
• Tongue: English
• Weight: 368 KB
• Volume: 32
• Category: Article
• ISSN: 0265-9247
• DOI: 10.1002/bies.201000027

✦ Synopsis

Abstract

Recent results confirm that long‐term expression of therapeutic transgenes can be achieved by using a transposon‐based system in primary stem cells and in vivo. Transposable elements are natural DNA transfer vehicles that are capable of efficient genomic insertion. The latest generation, Sleeping Beauty transposon‐based hyperactive vector (SB100X), is able to address the basic problem of non‐viral approaches – that is, low efficiency of stable gene transfer. The combination of transposon‐based non‐viral gene transfer with the latest improvements of non‐viral delivery techniques could provide a long‐term therapeutic effect without compromising biosafety. The new challenges of pre‐clinical research will focus on further refinement of the technology in large animal models and improving the safety profile of SB vectors by target‐selected transgene integration into genomic “safe harbors.” The first clinical application of the SB system will help to validate the safety of this approach.